

REGISTERED OFFICE

GRANULES INDIA LTD., 2nd Floor, 3rd Block, My Home Hub,

Madhapur, Hyderabad – 500 081, Telangana, INDIA.

Tel: +91 40 69043500, Fax: +91 40 23115145, mail@granulesindia.com, www.granulesindia.com

CIN: L24110TG1991PLC012471

Dated June 30, 2023

To,

National Stock Exchange of India Limited

BSE Limited

Symbol: NSE: GRANULES; BSE: 532482

Sub: Granules India's Unit IV facility located at Visakhapatnam completed the US FDA inspection.

Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir,

Please be informed that Company's Unit IV facility located at Visakhapatnam, Andhra Pradesh, India has successfully completed the US FDA's Pre-Approval Inspection (PAI) and GMP audit from 26th June 2023 to 30th June 2023 with zero (0) 483 observations.

Unit IV facility located at Visakhapatnam manufactures Active Pharmaceutical Ingredients (API).

This is for your information and dissemination to the members of the exchange.

Thanking You.

Yours sincerely,

For GRANULES INDIA LIMITED

CHAITANYA TUMMALA (COMPANY SECRETARY & COMPLIANCE OFFICER)